Mevalonate Blockade in Cancer Cells Triggers CLEC9A+ Dendritic Cell-Mediated Antitumor Immunity

0
125
Investigators showed that inhibition of the hyperactive mevalonate (MVA) metabolic pathway in tumor cells elicited type 1 classical dendritic cells-mediated tumor recognition and antigen cross-presentation for antitumor immunity.
[Cancer Research]
Xu, F., Wang, Z., Zhang, H., Chen, J., Wang, X., Cui, L., Xie, C., Li, M., Wang, F., Zhou, P., Liu, J., Huang, P., Xia, X., & Xia, X. (2021). Mevalonate blockade in cancer cells triggers CLEC9A+ dendritic cell-mediated antitumor immunity. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-3977 Cite
Abstract